We are live on ! Find out more
Victory Capital Management

Victory Capital Management Portfolio holdings

AUM $156B
1-Year Est. Return 27.51%
This Fund
S&P 500
This Quarter Est. Return
+4.92%
1 Year Est. Return
+27.51%
3 Year Est. Return
+75.53%
5 Year Est. Return
+102.92%
10 Year Est. Return
+480.77%
AUM
$47B
AUM Growth
+$1.15B
Cap. Flow
-$971M
Cap. Flow %
-2.07%
Top 10 Hldgs %
6.79%
Holding
1,899
New
95
Increased
1,009
Reduced
562
Closed
78

Sector Composition

Rank Sector Weight
1 Financials 17.95%
2 Industrials 14.14%
3 Technology 13.58%
4 Consumer Discretionary 11.68%
5 Healthcare 9.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STML
1751
DELISTED
Stemline Therapeutics, Inc.
STML
$22K ﹤0.01%
1,398
-460
-25% -$8.21K
MTZ icon
1752
MasTec
MTZ
$20.6B
$21K ﹤0.01%
418
-740,335
-100% -$35.8M
RIGL icon
1753
Rigel Pharmaceuticals
RIGL
$686M
$20K ﹤0.01%
705
XLP icon
1754
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.9B
$20K ﹤0.01%
379
-872
-70% -$44.3K
OLBK
1755
DELISTED
Old Line Bancshares, Inc.
OLBK
$20K ﹤0.01%
561
-17
-3% -$582
CLLS
1756
Cellectis
CLLS
$287M
$19K ﹤0.01%
683
SKT icon
1757
Tanger
SKT
$4.66B
$18K ﹤0.01%
765
CBAY
1758
DELISTED
Cymabay Therapeutics
CBAY
$18K ﹤0.01%
+1,322
New +$16.5K
FOMX
1759
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$18K ﹤0.01%
3,583
CSTE icon
1760
Caesarstone
CSTE
$73.3M
$16K ﹤0.01%
1,087
LCNB icon
1761
LCNB Corp
LCNB
$284M
$16K ﹤0.01%
833
-25
-3% -$480
ABEO icon
1762
Abeona Therapeutics
ABEO
$362M
$15K ﹤0.01%
37
CBAN icon
1763
Colony Bankcorp
CBAN
$466M
$13K ﹤0.01%
+791
New +$12.9K
FLO icon
1764
Flowers Foods
FLO
$1.52B
$13K ﹤0.01%
+608
New +$13K
NEWR
1765
DELISTED
New Relic, Inc.
NEWR
$13K ﹤0.01%
+126
New +$11.2K
CDTX
1766
DELISTED
Cidara Therapeutics
CDTX
$11K ﹤0.01%
110
ESPR
1767
DELISTED
Esperion Therapeutics
ESPR
$11K ﹤0.01%
282
TLGT
1768
DELISTED
Teligent, Inc
TLGT
$11K ﹤0.01%
331
XLI icon
1769
State Street Industrial Select Sector SPDR ETF
XLI
$33.1B
$10K ﹤0.01%
145
-10
-6% -$742
CLVS
1770
DELISTED
Clovis Oncology, Inc.
CLVS
$9K ﹤0.01%
189
-14,440
-99% -$702K
ACAD icon
1771
Acadia Pharmaceuticals
ACAD
$4.41B
$8K ﹤0.01%
513
AGEN
1772
Agenus
AGEN
$330M
$8K ﹤0.01%
188
WPG
1773
DELISTED
Washington Prime Group Inc.
WPG
$8K ﹤0.01%
114
KDNY
1774
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$7K ﹤0.01%
210
UE icon
1775
Urban Edge Properties
UE
$2.85B
$5K ﹤0.01%
237

Similar funds

Victory Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Victory Capital Management held 1,899 positions worth $47B, up 2.5% from $45.8B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.

Victory Capital Management's Q2 2018 filing shows 95 new, 1,009 increased, 562 reduced and 78 closed positions. Its largest new stake was Wells Fargo 7.5% Non Cumv Perp Conv: 56,038 shares worth $70.6M. The largest sale was Keysight, an estimated $104M.

By sector, the portfolio is most concentrated in Financials at 18% of assets, down from 19% a quarter earlier, followed by Industrials and Technology.

  • Victory Capital Management's largest Q2 2018 buy was Wells Fargo 7.5% Non Cumv Perp Conv: 56,038 shares worth $70.6M.
  • Victory Capital Management added most to State Street SPDR S&P MIDCAP 400 ETF Trust in Q2 2018, an estimated $110M increase.
  • Victory Capital Management's biggest Q2 2018 reduction was Keysight, cutting an estimated $104M.
  • Victory Capital Management fully exited Liberty Broadband Class C in Q2 2018, selling an estimated $50.7M.
  • Victory Capital Management's ten largest holdings make up 6.8% of its $47B portfolio in Q2 2018.
  • Victory Capital Management opened 95 new positions and closed 78 in Q2 2018.
  • Victory Capital Management's portfolio value rose 2.5% quarter-over-quarter to $47B.

Based on Victory Capital Management's 13F filing for Q2 2018, filed 2 Aug 2018.